Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Targeting the novel SALL4/CBL-B pathway by HDAC inhibitor MS-275 in lung cancer


ABSTRACT: The overall survival of lung cancer patients remains dismal despite the availability of targeted therapies. Oncofetal protein SALL4 is a novel cancer target. We herein report that SALL4 was aberrantly expressed in a subset of lung cancer patients with poor survival. SALL4 silencing by RNA interference or SALL4 peptide inhibitor treatment led to impaired lung cancer cell growth. Expression profiling on SALL4-knockdown cells demonstrated that both the EGFR and IGF1R signaling pathways were affected. Further studies revealed that SALL4 suppresses these pathways indirectly by repressing CBL-B. Connectivity Map analysis revealed HDAC inhibitor MS-275 as a potential drug in treating SALL4-expressing cancers and this was confirmed using 17 lung cancer cell lines. In summary, we report for the first time that MS-275 can target the novel SALL4/CBL-B pathway in lung cancer. This lays the foundation for future clinical studies to evaluate the therapeutic efficacy of MS-275 in SALL4-positive lung cancer patients. Cells from human lung carcinoma cell line H661 with wildtype scrambled controls or Sall4 knockdown were used for RNA extraction and hybridization on Affymetrix microarrays.

ORGANISM(S): Homo sapiens

SUBMITTER: Henry Yang 

PROVIDER: E-GEOD-68959 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Similar Datasets

2015-05-16 | GSE68959 | GEO
2012-02-22 | E-GEOD-35965 | biostudies-arrayexpress
| PRJNA284164 | ENA
2021-01-05 | E-MTAB-9202 | biostudies-arrayexpress
2008-05-17 | E-GEOD-10734 | biostudies-arrayexpress
| 2011932 | ecrin-mdr-crc
2016-08-02 | PXD003614 | Pride
| 2006457 | ecrin-mdr-crc
2012-02-22 | GSE35965 | GEO
2023-01-04 | E-MTAB-11519 | biostudies-arrayexpress